The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...